Hero

Celyad Announces February and March 2020 Conference Schedule

1

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders

2

Letter to Shareholders

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

3

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

4

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Announces February and March 2020 Conference Schedule

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders - January 2020

Letter to Shareholders - January 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Discover all news

Carousel

Social Feed

Celyad Announces February and March 2020 Conference Schedule. https://t.co/1hoT8DT7xD https://t.co/J4Kjxy9Dzs

12 hours ago

Celyad Announces February and March 2020 Conference Schedule. https://t.co/1hoT8DT7xD https://t.co/J4Kjxy9Dzs

RT @KarenJagoda: #podcast Filippo Petti @CelyadSA on developing #CAR_T therapies that use #NKcell receptors to generate a broad targeting #…

1 week ago

RT @KarenJagoda: #podcast Filippo Petti @CelyadSA on developing #CAR_T therapies that use #NKcell receptors to generate a broad targeting #…

"Several approaches can be used to tackle CoG (of manufacturing CAR-T cell therapies), including labor and raw mate… https://t.co/AkEQmP0v1t

1 week ago

"Several approaches can be used to tackle CoG (of manufacturing CAR-T cell therapies), including labor and raw mate… https://t.co/AkEQmP0v1t

#Cancer affects us all. Join us and @UICC in taking action towards a future without #cancer https://t.co/ewKKwSu6bw https://t.co/lqETaMKGLg

1 week ago

#Cancer affects us all. Join us and @UICC in taking action towards a future without #cancer https://t.co/ewKKwSu6bw https://t.co/lqETaMKGLg

Celyad Announces February and March 2020 Conference Schedule. https://t.co/1hoT8DT7xD https://t.co/J4Kjxy9Dzs

12 hours ago

Celyad Announces February and March 2020 Conference Schedule. https://t.co/1hoT8DT7xD https://t.co/J4Kjxy9Dzs

RT @KarenJagoda: #podcast Filippo Petti @CelyadSA on developing #CAR_T therapies that use #NKcell receptors to generate a broad targeting #…

1 week ago

RT @KarenJagoda: #podcast Filippo Petti @CelyadSA on developing #CAR_T therapies that use #NKcell receptors to generate a broad targeting #…

"Several approaches can be used to tackle CoG (of manufacturing CAR-T cell therapies), including labor and raw mate… https://t.co/AkEQmP0v1t

1 week ago

"Several approaches can be used to tackle CoG (of manufacturing CAR-T cell therapies), including labor and raw mate… https://t.co/AkEQmP0v1t

#Cancer affects us all. Join us and @UICC in taking action towards a future without #cancer https://t.co/ewKKwSu6bw https://t.co/lqETaMKGLg

1 week ago

#Cancer affects us all. Join us and @UICC in taking action towards a future without #cancer https://t.co/ewKKwSu6bw https://t.co/lqETaMKGLg